Enveda Biosciences
PrivateLast Round
Series E
Sep 23, 2026
Est. Valuation
$2B
Total Funding Raised
$911.9M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Enveda Biosciences is a biotechnology company that utilizes an AI-powered drug discovery platform to analyze natural samples for chemical structure and biological activity to develop novel small-molecule medicines.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Enveda Biosciences Comparables
Compare Enveda Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Insitro | 81% | |
| Valo Health | 81% | |
| Terray Therapeutics | 80% |
Enveda Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series E | Sep 23, 2026 | ||||
| Series D | Sep 4, 2025 | ||||
| Series C Extension | Feb 26, 2025 | ||||
| Series C | Feb 26, 2025 | ||||
| Series B Extension | Jun 14, 2024 | ||||
Series B Extension | Apr 20, 2023 |
Key People
Founding team and executive leadership
Enveda Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| S32 | Series B Extension |
| Surveyor Capital | Series E |
| Alderline Group | Series E |
| ICONIQ Capital | Series E |
| Digitalis Ventures | Series E |
| Lingotto | Series B Extension, Series D, Series C |
| Global Village | Seed, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 23, 2026
$311M round led by Catalio Capital Management.
- Apr 8, 2026
ENV-294 is one of the lead assets in clinical trials.
Recent news
Latest coverage and updates
- receives_financingSep 24, 2026
Enveda received financing of $311M in Series C on Jul 1st '26.
- has_valuationSep 24, 2026
Enveda had valuation of $2B on Sep 23rd '26.
- hiresSep 23, 2026
On Sep 23rd '26, Enveda adds Catalio co-founder and managing partner George Petrocheilos to its board as part of its $311 million Series E financing led by Catalio Capital Management.
- is_developingSep 23, 2026
Enveda is developing PRISM on Jul 1st '26.
- launchesAug 24, 2026
Enveda launched compound that mimics the physiological effects of exercise on Aug 24th '26.
Enveda Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Enveda Biosciences's valuation, stock price, and market status.
Is Enveda Biosciences a public or private company?
Enveda Biosciences is a private company.
What is the current stock price of Enveda Biosciences?
Enveda Biosciences is a private company, so its shares have no public market price. Caplight tracks Enveda Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Enveda Biosciences worth (valuation)?
Enveda Biosciences's valuation is estimated at $2.0B based on funding round data.
Can I buy Enveda Biosciences stock?
Enveda Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Enveda Biosciences's last funding round?
Enveda Biosciences's most recent funding round was Series E on September 23, 2026.
Who are the main investors in Enveda Biosciences?
Key investors in Enveda Biosciences include Lux Capital, Catalio Capital Management, Premji Invest, Dimension, FPV Ventures.
Will Enveda Biosciences IPO soon?
No public IPO plans have been announced for Enveda Biosciences.
How can I track Enveda Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Enveda Biosciences's shares on secondary markets.